Recent Updates
Recently added Catalysts

62.5/

Phase 3

Pulmonary Disease, Chronic Obstructive | Small molecule | Other |GSK plc|Last Updated: Aug 6, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment1,538
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01313650A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPDPHASE3 COMPLETED 1,538Mar 1, 2011Apr 5, 2012Aug 6, 2018165 United States, Bulgaria +11
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)
Baseline and Day 169

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.

Secondary Endpoints
Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24)
Day 168 (Week 24)
Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168
Baseline and Day 168
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GSK573719/GW642444EXPERIMENTAL62.5/25mcg
GSK573719EXPERIMENTAL62.5mcg
GW642444EXPERIMENTAL25mcg
PlaceboPLACEBO_COMPARATORPlacebo
Interventions
NameTypeDescription
62.5/25mcgDRUGGSK573719/GW64244
62.5mcgDRUGGSK573719
25mcgDRUGGW642444
PlaceboDRUGPlacebo
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites165

Inclusion Criteria: * Diagnosis of COPD * 10 pack-year or greater history of cigarette smoking * Post-bronchodilator FEV1/FVC of \<0.7 * Predicted FEV1 of 70% of normal or less * Modified Medical Research Council (mMRC) dyspnea score of 2 or greater Exclusion Criteria: * Women who are pregnant, l...

Countries:United StatesBulgariaCanadaChileCzechiaGreeceJapanMexicoPolandRussiaSouth AfricaSpainThailand
Unlock Eligibility Criteria